Theratechnologies Inc. re-affirmed revenue guidance for the fiscal year of 2022. For the year, the company is on track to be in the range of $79 million - $82 million, or growth of the commercial portfolio to be in the range of 13% and 17%, as compared to the 2021 fiscal year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.68 CAD | -2.89% | +1.20% | -21.50% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.50% | 56.14M | |
-0.38% | 92.26B | |
-3.16% | 38.11B | |
+64.83% | 26.51B | |
-13.98% | 15.75B | |
-5.40% | 13.36B | |
-11.38% | 11.65B | |
+156.85% | 9.78B | |
-49.84% | 10.12B | |
+2.32% | 8.84B |
- Stock Market
- Equities
- TH Stock
- News Theratechnologies Inc.
- Theratechnologies Inc. Re-Affirms Revenue Guidance for the Fiscal Year of 2022